Rinsho Shinkeigaku (Clinical Neurology)

Symposium 1

α-synuclein as biomarker

Kenjiro Ono, M.D., Ph. D.1) and Masahito Yamada, M.D., Ph.D.1)

1)Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science

Although α-synuclein protein (αS) aggregates from a monomer to assemblies such as oligomer, protofibril and mature fibril, the early intermediate aggregate, that is, oligomer has been considered to be most toxic species in recent reports. While it was reported that αS concentration in cerebrospinal fluid was decreased significantly in the patients with Parkinson's disease (PD) and dementia with Lewy bodies, there were reports that αS oligomer concentration was elevated in cerebrospinal fluid of PD patients. Moreover, it was supposed that αS oligomer concentration was also elevated in blood of PD patients. Further studies of αS in cerebrospinal fluid and blood would lead to establishment of the significance of αS as a biomarker for α-synucleinopathies including PD.
Full Text of this Article in Japanese PDF (629K)

(CLINICA NEUROL, 53: 983|985, 2013)
key words: alpha-synuclein protein, aggregation, oligomer, cerebrospinal fluid

(Received: 29-May-13)